Delivery Technologies for Cancer Immunotherapy

Purpose: Immunotherapy has become powerful but broad implementation limited by inability to control immune modulation; serious adverse effects including autoimmunity, nonspecific inflammation. Need delivery technologies to improve efficacy and safety.

Hypothesis: If advanced biomaterials/delivery systems (nanoparticles, implants, scaffolds, cell-based platforms) are engineered for targeted/localized/controlled release, then cancer immunotherapies can be harnessed with improved potency and reduced toxic side effects.

Aims: - Overview main classes of cancer immunotherapy and clinical status, advantages/disadvantages. - Review novel delivery platforms to overcome clinical translation challenges. - Analyze opportunities/challenges integrating delivery technologies into cancer immunotherapy. - Discuss clinical translation and future directions.

Delivery system: List classes: nanoparticles/conjugates; biomaterials localized; T cell therapy delivery. Specific examples.

Approach: Narrative review; preclinical/clinical literature; mouse models etc.

Key methods: Techniques across cited studies: flow cytometry, IVIS, tumor growth/survival, cytokine assays, microscopy, MRI/PET for EPR, etc.

Key results: Numbers.

Interpretation: As above.

Limitations: As above. Need maybe mention "Table 1" FDA approved immunotherapies, "Table 2" characteristics. Good. Need no additional commentary. Final answer. Ensure not too long. Could be around 1500 words? Desired oververbosity 5 maybe ~1000-1500. Let's produce.